SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 15th, 2020 • Tauriga Sciences, Inc. • Medicinal chemicals & botanical products • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 17, 2020 by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and ADAR ALEF, LLC, a New York limited liability company, with its address at 38 Olympia Ln, Monsey, NY 10952 (the “Buyer”).
5% FIXED CONVERTIBLE PROMISSORY NOTE OF TAURIGA SCIENCES, INC.Note Agreement • April 15th, 2020 • Tauriga Sciences, Inc. • Medicinal chemicals & botanical products • Puerto Rico
THIS NOTE is a duly authorized Fixed Convertible Promissory Note of Tauriga Sciences, Inc., a corporation duly organized and existing under the laws of the State of Florida (the “Company”), designated as the Company’s 5% Fixed Convertible Promissory Note due September 23, 2020 (“Maturity Date”) in the face amount of $43,050 (the “Note”).
Collaboration AgreementCollaboration Agreement • April 15th, 2020 • Tauriga Sciences, Inc. • Medicinal chemicals & botanical products
This Collaboration Agreement (“Agreement”) is entered into as of April 3, 2020 (the “Effective Date”) by and between Tauriga Sciences Inc. (“Tauriga”) and Aegea Biotechnologies Inc. (“Aegea”) for the purpose of together developing a Rapid, Multiplexed Novel Coronavirus (COVID-19) Point of Care Test with Superior Sensitivity and Selectivity (the “SARS-Col 2 Test”).
